Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on November 25, 2025, and filed on November 26, 2025. The filing details a share repurchase executed through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not contain revenue, profit, cash flow, margin, or debt data.
- Shares Purchased (Nov 25, 2025): 170,000 ordinary shares.
- Price Range: Lowest 1,778.00 GBp; Highest 1,807.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,789.59 GBp.
- Total Buyback Since Sept 30, 2025: 10,478,000 ordinary shares.
- Treasury Shares Held: 235,942,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,079,489,083 ordinary shares.
- Treasury Voting Rights: 5.78% of total voting rights.
Material Changes
Following the November 25 transaction, the company's treasury shareholding increased to 235,942,844 shares. Consequently, the number of ordinary shares in issue (excluding treasury shares) stands at 4,079,489,083. The percentage of voting rights attributable to treasury shares is confirmed at 5.78%.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results.
Investor Verification Checklist
- Verify the total cumulative buyback volume against the September 30, 2025, programme announcement.
- Confirm the updated share count (4,079,489,083) for calculating ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Review the 5.78% treasury voting rights figure to assess potential dilution or control implications.
- Check the specific trading venues (BATE, CHIX, XLON) for execution details if analyzing market impact.